A comparative study between a power and a connectivity sEEG biomarker for seizure-onset zone identification in temporal lobe epilepsy
Background: Ictal stereo-encephalography (sEEG) biomarkers for seizure onset zone (SOZ) localization can be classified depending on whether they target abnormalities in signal power or functional connectivity between signals, and they may depend on the frequency band and time window at which they ar...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:10230/70794 |
| Acceso en línea: | http://hdl.handle.net/10230/70794 http://dx.doi.org/10.1016/j.jneumeth.2024.110238 |
| Access Level: | acceso abierto |
| Palabra clave: | Epilepsy Functional connectivity Intracranial EEG Power spectrum analysis Seizure onset zone identification sEEG |
| Sumario: | Background: Ictal stereo-encephalography (sEEG) biomarkers for seizure onset zone (SOZ) localization can be classified depending on whether they target abnormalities in signal power or functional connectivity between signals, and they may depend on the frequency band and time window at which they are estimated. New method: This work aimed to compare and optimize the performance of a power and a connectivity-based biomarker to identify SOZ contacts from ictal sEEG recordings. To do so, we used a previously introduced power-based measure, the normalized mean activation (nMA), which quantifies the ictal average power activation. Similarly, we defined the normalized mean strength (nMS), to quantify the ictal mean functional connectivity of every contact with the rest. The optimal frequency bands and time windows were selected based on optimizing AUC and F2-score. Results: The analysis was performed on a dataset of 67 seizures from 10 patients with pharmacoresistant temporal lobe epilepsy. Our results suggest that the power-based biomarker generally performs better for the detection of SOZ than the connectivity-based one. However, an equivalent performance level can be achieved when both biomarkers are independently optimized. Optimal performance was achieved in the beta and lower-gamma range for the power biomarker and in the lower- and higher-gamma range for connectivity, both using a 20 or 30 s period after seizure onset. Conclusions: The results of this study highlight the importance of this optimization step over frequency and time windows when comparing different SOZ discrimination biomarkers. This information should be considered when training SOZ classifiers on retrospective patients' data for clinical applications. |
|---|